GlassScriptPhysician profile
Hemani Ticku
NPI 1598318313
$1,108.76
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $308 · 2023: $222 · 2024: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $685.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $334.86 | 2023-2024 | Rystiggo, Zilbrysq |
| Genzyme Corporation | $147.56 | 2021-2023 | |
| Genentech USA, INC. | $83.69 | 2023-2024 | Ocrevus, Evrysdi, Enspryng |
| Emd Serono, INC. | $76.90 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $73.27 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $72.77 | 2023-2024 | Ultomiris, Soliris |
| Horizon Therapeutics Plc | $59.97 | 2022 | |
| Argenx US, INC. | $57.47 | 2023 | Vyvgart |
| Takeda Pharmaceuticals U.S.A., INC. | $42.00 | 2022-2024 | Hyqvia |
| Averitas Pharma INC. | $41.73 | 2023-2024 | Qutenza |
| Lilly USA, LLC | $35.50 | 2024 | Amyvid |
| Biogen, INC. | $35.25 | 2022-2024 | Qalsody, Spinraza |
| Biohaven Pharmaceutical Holding Company LTD. | $31.42 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hemani Ticku listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.